Drug intelligence / Profile preview

WS018

Development stage: Unknown
Lead developer: Waterstone Pharmaceuticals
Modality: Small Molecules

Overview

WS018 is an investigational small molecule developed by Waterstone Pharmaceuticals (Wuhan) Co., Ltd. for the treatment of obesity. As of the latest pipeline updates, the compound is in the early stages of clinical development, categorized as being in the IND-enabling or Phase 1 stage. While it is a key component of Waterstone's metabolic disease portfolio—which also includes candidates for hyperlipidemia and hyperuricemia—the specific biological target and mechanism of action for WS018 remain proprietary and have not been disclosed in public documentation.

Beyond the preview

Go deeper on WS018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WS018.

Explore the full profile